Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate
Aptorum Group Limited (NASDAQ:APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically, two…
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM)) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces further positive results of its ongoing Phase 1
58 Biggest Movers From Friday
Gainers
CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
54 Biggest Movers From Yesterday
Gainers
Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended April 3, 2021.
52 Biggest Movers From Yesterday
Gainers
Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
Aptorum’s Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study
Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1…
Schedule For Benzinga’s Global Small Cap Conference Friday, May 14, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda
* the list below is limited to some of the publicly-traded companies that will be presenting